Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMYMP) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $2.44.

  • Bristol Myers Squibb's Debt to Equity fell 1953.9% to $2.44 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.44, marking a year-over-year decrease of 1953.9%. This contributed to the annual value of $2.44 for FY2025, which is 1953.9% down from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Debt to Equity is $2.44, which was down 1953.9% from $2.63 recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Debt to Equity high stood at $3.36 for Q1 2024, and its period low was $0.87 during Q4 2022.
  • Moreover, its 5-year median value for Debt to Equity was $1.29 (2022), whereas its average is $1.85.
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 24799.36% in 2024, then tumbled by 1953.9% in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Debt to Equity stood at $1.0 in 2021, then decreased by 13.32% to $0.87 in 2022, then grew by 0.0% to $0.87 in 2023, then skyrocketed by 247.99% to $3.03 in 2024, then dropped by 19.54% to $2.44 in 2025.
  • Its last three reported values are $2.44 in Q4 2025, $2.63 for Q3 2025, and $2.81 during Q2 2025.